Page 29 - Pfizer

EU health regulator reviewing Pfizer-BioNTech Covid-19 vaccine in real time

The announcement by the European Medicines Agency (EMA) could speed up the process of approving a successful vaccine in the bloc

Pfizer partner BioNTech sees no role for its vaccine in UK challenge trial

Pfizer's German development partner BioNTech on Thursday joined other leading Covid-19 vaccine developers in ruling out participation in British plans to test experimental inoculations

Johnson & Johnson kicks off giant study of single shot Covid-19 vaccine

J&J became the fourth vaccine maker to move its candidate into late-stage human studies in the US

Trump suggests Pfizer could win first US approval for Covid-19 vaccine

'Pfizer's doing really well', Trump said in an interview

Trump suggests Pfizer could win Covid vaccine approval, J&J to come later

WASHINGTON (Reuters) - U.S. President Donald Trump on Monday suggested Pfizer Inc could secure the first U.S. approval of a COVID-19 vaccine in coming weeks, saying a contender by Johnson & Johnson could come later.

Moderna and Pfizer reveal secret blueprints for virus vaccine trials

The companies, Moderna and Pfizer, revealed details about how participants are being selected and monitored

Pfizer vaccine trial bets on early win against coronavirus, documents show

Pfizer's clinical trial protocol outlines for the company, scientists and regulators how the drugmaker could show that its vaccine meets efficacy and safety standards set by USFDA

Pfizer, BioNTech to expand phase three trial for coronavirus vaccine

The US Food and Drug Administration (FDA) will have to approve the change in the Phase 3 Covid-19 vaccine trial before it goes into effect

US, European Covid-19 vaccine developers pledge to uphold testing rigour

The promise to play by established rules underlines a highly politicised debate over what action is needed to rein in Covid-19 quickly and to jumpstart global business and trade

BioNTech, Pfizer begin German part of coronavirus vaccine study

Biotech firm BioNTech said on Monday it widened an ongoing pivotal global study of its Covid-19 vaccine candidate to include testing in its home country of Germany

Pfizer, BioNTech Covid-19 vaccine on track for regulatory review in October

The companies said the vaccine was well tolerated with mild to moderate fever in fewer than 20% of the participants

Covid-19 vaccine makers must deliver to US in time to get full payments

The Cambridge, Massachusetts, biotech's $1.5-billion deal pays out in full if its vaccine receives regulatory clearance by January 31, 2021

Pfizer-BioNTech vaccine candidate induces robust immune response: Study

It is one of several RNA vaccine candidates that are being studied in parallel for selection to advance to a trial of their safety and efficacy

Rich nations rush to lock up Covid vaccines: What about rest of the world?

Moves by the US and UK to secure supplies from Sanofi and partner GlaxoSmithKline Plc, and another pact between Japan and Pfizer Inc., are the latest in a string of agreements

Pfizer, BioNTech to supply 120 mn doses of coronavirus vaccine to Japan

BioNTech and Pfizer on Monday began a large, late-stage trial of their vaccine candidate to demonstrate its efficacy

Pfizer and BioNTech start late-stage study of lead Covid-19 shot

The move pushes the New York-based pharmaceutical giant and its German partner closer to bringing a vaccine to market, and places them alongside frontrunners like Moderna Inc

Pfizer optimistic about rebound in drug sales, raises 2020 profit forecast

The report comes at the start of a busy week of US pharmaceutical earnings, with investors focusing on updates on the development of vaccines and treatments for the pandemic

Moderna, Pfizer begin Covid-19 vaccine trials, eye year-end launches

The study is expected to include about 120 sites globally and could include up to 30,000 participants. It will include regions heavily impacted by Covid-19

Pfizer profit before tax down marginally to Rs 173 crore in June quarter

Revenue stood at Rs 514.89 crore against Rs 544.40 crore for the same period a year ago

US to pay Pfizer, BioNTech $1.95 bn for 100 mn Covid-19 vaccine doses

The companies will not receive any money from the government unless their vaccine succeeds in large clinical trials